Roche's Fenebrutinib Receives FDA Priority Review for Multiple Sclerosis Treatment

The FDA has granted priority review to Roche's fenebrutinib, an investigational BTK inhibitor, for both relapsing and primary progressive multiple sclerosis. This decision follows Phase III studies showing the drug reduced relapses and showed a trend in delaying disability progression. The priority review could accelerate access to a new treatment option for MS patients.